QIAGEN Reports Results for Third Quarter and First Nine Months of 2017

VENLO, the Netherlands, November 6, 2017

• Solid Q3 2017 performance in line with full-year ambitions: 
• Net sales $364.0 million (+7% actual, +7% CER); adjusted net sales
  $364.4 million (+8% actual, +7% CER vs. +7% CER guidance) 
• EPS $0.21; adjusted EPS $0.32 ($0.32 CER), adjusted EPS excluding
  restructuring charge $0.32 ($0.32 CER vs. $0.32-0.33 CER guidance) 
• Nine-month 2017 free cash flow of $146.1 million impacted by $41 million cash restructuring charges 
• Solid growth of Sample to Insight portfolio led by QuantiFERON latent TB test growing above 25% CER annual target, complemented by QIAsymphony, human ID / forensics and infectious disease testing portfolio 
• $300 million share repurchase commitment completed ahead of end-2017 goal 
• New initiative in China to focus on high-growth areas and streamline portfolio 
• Reaffirming 2017 adjusted EPS target of $1.25-1.27 CER before restructuring;
  ~7% CER adjusted net sales growth excluding changes in China portfolio  

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the third quarter and first nine months of 2017, delivering on goals for improvements in adjusted net sales and adjusted earnings.

Click here for the full press release

https://corporate.qiagen.com/newsroom/press-releases/2017/2017-11-06-Q3results?sc_lang=en

Contacts
Investor Relations:
John Gilardi
Vice President Corporate Communications and Investor Relations
+49-2103-29-11711
+1-240-686-2222

Dr. Sarah Fakih
Associate Director Investor Relations
+49-2103-29-11457
Email: ir@qiagen.com
ir.qiagen. com

Public Relations:
Dr. Thomas Theuringer
Senior Director Public Relations and Digital Communications
+49-2103-29-11826
+1-240-686-7425
Email: pr@qiagen.com
pr.qiagen.com

http://www.twitter.com/qiagen